Funding for this research was provided by:
Sir Jules Thorn Charitable Trust
Brain Research UK
Received: 6 July 2020
Accepted: 8 September 2020
First Online: 25 September 2020
Ethics approval and consent to participate
: Data for the patients involved was collected as part of a registered service evaluation University Hospitals Birmingham National Health Service Foundation Trust, United Kingdom (Registered Code, Clinical Audit Registration and Management System: CARMS-15001) with data collection approved by NHS National Research Ethics Committee (14/LO/1208), IIH:LIFE study.
: Written informed consent was obtained from the patient for publication of the accompanying ophthalmic images and the case report.
: Edwards has received speaker fees and Honoria from Novartis, Teva, Eli Lily and Allergan on headache treatments but not related to IIH. Mollan has received Honoria from Novartis for speaking on topics unrelated to this drug, but within a National headache network meeting (November 2019). Sinclair has received speaker fees and Honoraria from Novartis (erenumab) and Allergan (BOTOX), in addition, Invex therapeutics, company director with salary and stock options (2019, 2020). Grech, Consultancy work for Invex therapeutics (2020). Authors declare no other financial relationships with any organisations that might have an interest in the submitted work; and no other relationships or activities that could appear to have influenced the submitted work.